Danaher Co. (NYSE:DHR) Shares Sold by Parallel Advisors LLC

Parallel Advisors LLC trimmed its position in shares of Danaher Co. (NYSE:DHR) by 5.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,646 shares of the conglomerate’s stock after selling 737 shares during the period. Parallel Advisors LLC’s holdings in Danaher were worth $2,903,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. FMR LLC increased its position in Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Danaher during the fourth quarter worth approximately $391,172,000. Van ECK Associates Corp increased its position in shares of Danaher by 6,862.7% in the fourth quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock worth $213,452,000 after acquiring an additional 916,513 shares in the last quarter. Parnassus Investments LLC raised its stake in shares of Danaher by 31.8% in the 4th quarter. Parnassus Investments LLC now owns 3,105,388 shares of the conglomerate’s stock valued at $712,842,000 after acquiring an additional 749,136 shares during the period. Finally, Proficio Capital Partners LLC lifted its holdings in shares of Danaher by 29,287.7% during the 4th quarter. Proficio Capital Partners LLC now owns 588,929 shares of the conglomerate’s stock valued at $135,189,000 after acquiring an additional 586,925 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 11.10% of the company’s stock.

Danaher Stock Up 1.0 %

DHR stock opened at $212.78 on Tuesday. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70. The company has a 50 day moving average of $219.57 and a two-hundred day moving average of $240.07. The company has a market cap of $152.08 billion, a price-to-earnings ratio of 40.30, a PEG ratio of 2.66 and a beta of 0.82.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the business posted $2.09 earnings per share. On average, equities analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.60%. The ex-dividend date is Friday, March 28th. This is an increase from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio (DPR) is 24.24%.

Analyst Ratings Changes

Several analysts recently issued reports on DHR shares. The Goldman Sachs Group set a $250.00 price target on Danaher in a report on Wednesday, January 15th. Robert W. Baird dropped their target price on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Raymond James reaffirmed a “market perform” rating on shares of Danaher in a research report on Monday, February 3rd. Scotiabank initiated coverage on shares of Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective on the stock. Finally, Citigroup decreased their target price on shares of Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Six equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $277.76.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.